AZ Secures EU Fast-Tack Review For Nirsevimab

First Filing Worldwide Submitted To EMA For Novel Anti-RSV Immunization For All Infants

 
• By Maureen Kenny

There could be a regulatory decision on AstraZeneca and Sanofi's nirsevimab in the EU in H2 as a result of the European Medicines Agency speeding up its review of the marketing application for the potential new immunization against RSV in all infants.

Intubated child with RSV being cared for in ICU
Respiratory syncytial virus is a leading cause of hospitalization in all infants • Source: Alamy

More from Europe

More from Geography